Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Study explains how genetic mutations lead to development of Parkinson's disease

Researchers at Mount Sinai School of Medicine have discovered a way that mutations in a gene called LRRK2 may cause the most common inherited form of Parkinson's disease. The study, published online this month in the journal Public Library of Science, shows that upon specific modification called phosphorylation, LRRK2 protein binds to a family of proteins called 14-3-3, which has a regulatory function inside cells.

25 Mar 2011

Almac extends Pharma Services business unit to increase demand for storage capacity

In response to increased client demand for cold and dedicated frozen storage capacity for biopharmaceuticals, Almac's Pharma Services business unit has expanded its commercial facilities to include an additional 6124 sq ft of cold and frozen storage.

25 Mar 2011

Study: Short telomeres may predispose people to age-related diabetes

New evidence has emerged from studies in mice that short telomeres or "caps" at the ends of chromosomes may predispose people to age-related diabetes, according to Johns Hopkins scientists.

25 Mar 2011

HDL, BG Medicine to offer galectin-3 testing services for patients with heart failure

Health Diagnostic Laboratory, Inc. and BG Medicine, Inc., announced today an agreement under which HDL, Inc. will offer galectin-3 testing services based on the BG Medicine Galectin-3 Test.

25 Mar 2011

DNA "end-caps" length linked to diabetes risk: New role for short telomeres

New evidence has emerged from studies in mice that short telomeres or “caps” at the ends of chromosomes may predispose people to age-related diabetes, according to Johns Hopkins scientists.

24 Mar 2011

Rush scientific team selects BioFortis Labmatrix database to manage biomarker research activities

Dr. Victor Levenson, a radiation oncologist at Rush University Medical Center, Chicago, and his scientific team have recently selected Labmatrix to manage their biobanking and biomarker research activities at this top-ranking U.S. medical research institution. Labmatrix is a web-accessible collaborative scientific database software developed by BioFortis, Inc.

24 Mar 2011

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Aptiv Solutions and Cancer Genetics, Inc. (CGI) have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics.

24 Mar 2011

Almac to launch new services for clinical trial patient management

Almac announced today that its Clinical Technologies business unit, a global leader in clinical trial management, will launch a suite of new services designed to improve patient compliance and retention in clinical trials.

23 Mar 2011

New Neurotez method can predict genetic factors responsible for AD

The new Neurotez method will allow for an elegant and rapid way to screen a large number of patient-derived samples and measure the degree of confidence in predicting a subject's risk for getting Alzheimer's disease, based on her/his TOMM40/APOE haplotype.

22 Mar 2011

USPTO grants patent to HistoRx methods for digital microscopy standardization

HistoRx, Inc., announced today that the U.S. Patent and Trademark Office has granted a patent protecting the company's methods for standardization of digital microscopy instruments in order to go beyond imaging to generating high-quality reproducible data that precisely relates to biomarker concentrations in tissue sections.

22 Mar 2011

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, and NuGEN Technologies, Inc., a leader in innovative genomic samples preparation, today announced they will co-develop and co-market simple, seamlessly integrated workflows for gene expression profiling and target enrichment to enable researchers to more easily achieve high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace clinical specimens, such as formalin fixed paraffin embedded tissue (FFPE).

21 Mar 2011

Almac, Exco InTouch enter exclusive integrated patient management alliance

The Almac Group and Exco InTouch announced today that Almac's Clinical Technologies business unit, the leading provider of IXRS(R) (Interactive Voice and Web Response) services relating to patient and drug supply management, has formed an exclusive integrated patient management alliance with Exco InTouch, an innovative firm specializing in patient recruitment, retention, compliance and ePRO services.

21 Mar 2011

ACRIN, ECOG, NCI intent to merge their clinical cancer research programs

The American College of Radiology's Imaging Network and the Eastern Cooperative Oncology Group, National Cancer Institute Clinical Trials Cooperative Group members, today announced their intent to merge their clinical cancer research programs.

19 Mar 2011

UCLA researchers identify new biomarker that can help track amyloid beta in Alzheimer's

UCLA researchers have identified a new biomarker that could help them track how effectively the immune system is able to clear the brain of amyloid beta, which forms the plaques considered one of the hallmarks of Alzheimer's disease.

18 Mar 2011

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

Quest Diagnostics Incorporated, the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing on samples of patients in the state. It is believed to be the first molecular colorectal cancer detection method that employs a venal blood specimen to be approved by the state.

From Quest Diagnostics 18 Mar 2011

BUSM scientists identify new biomarker and melanoma treatment target

Researchers at Boston University School of Medicine, in collaboration with Johns Hopkins University, have identified a potential new biomarker and therapeutic target for melanoma.

18 Mar 2011

NextGen Sciences introduces multiplex protein assay for oncology biomarker discovery

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first multiple protein assay, plasmadiscovery41, for oncology biomarker discovery and qualification.

16 Mar 2011

Almac invests in two ZED automated inline wallet presses

Global Clinical Services provider Almac has announced an investment in two ZED automated inline wallet presses. Operating in Craigavon and Pennsylvania, the fully automated machines will drastically reduce timelines associated with the use of blister card packaging, when compared with current rotary press methods.

16 Mar 2011

Ventana, CST enter license agreement for personalized cancer diagnostics

Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.

From Cell Signaling Technology 16 Mar 2011

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford BioMedica plc, a leading gene therapy company, today announces that further analyses of the TroVax Renal Immunotherapy Survival Trial, a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology, Immunotherapy, the official journal of the Association for Cancer Immunotherapy.

15 Mar 2011

Biomarker News and Research

Further Reading

Study explains how genetic mutations lead to development of Parkinson's disease

Almac extends Pharma Services business unit to increase demand for storage capacity

Study: Short telomeres may predispose people to age-related diabetes

HDL, BG Medicine to offer galectin-3 testing services for patients with heart failure

DNA "end-caps" length linked to diabetes risk: New role for short telomeres

Rush scientific team selects BioFortis Labmatrix database to manage biomarker research activities

Aptiv Solutions, Cancer Genetics partner to deliver comprehensive solutions for clinical trials in oncology

Almac to launch new services for clinical trial patient management

New Neurotez method can predict genetic factors responsible for AD

USPTO grants patent to HistoRx methods for digital microscopy standardization

WaferGen, NuGEN collaborate to develop integrated workflows for gene expression profiling and target enrichment

Almac, Exco InTouch enter exclusive integrated patient management alliance

ACRIN, ECOG, NCI intent to merge their clinical cancer research programs

UCLA researchers identify new biomarker that can help track amyloid beta in Alzheimer's

Quest Diagnostics ColoVantage molecular colorectal cancer detection test receives New York State approval

BUSM scientists identify new biomarker and melanoma treatment target

NextGen Sciences introduces multiplex protein assay for oncology biomarker discovery

Almac invests in two ZED automated inline wallet presses

Ventana, CST enter license agreement for personalized cancer diagnostics

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo